Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.

Cell death & disease - 8 Feb 2022

Hu Linfei, Zhang Jun, Tian Mengran, Kang Ning, Xu Guangwei, Zhi Jingtai, Ruan Xianhui, Hou Xiukun, Zhang Wei, Yi Jiaoyu, Ma Weike, Chang Luchen, Tang Tao, Zheng Xiangqian, Wei Xi, Gao Ming

Abstract excerpt

The use of the BRAF inhibitor vemurafenib exhibits drug resistance in the treatment of thyroid cancer (TC), and finding more effective multitarget combination therapies may be an important solution. In the present study, we found strong correlations between Ref-1 high expression and BRAF mutation, lymph node metastasis, and TNM stage. The oxidative stress environment induced by structural activation of BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to DNA-(Apurinic or Apyrimidinic Site) Lyase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 35136031
DOI: 10.1038/s41419-022-04550-0
PMCID: PMC8825860

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.PMID 35136031Read ↗

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Semantic proximity Read ↗

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.Semantic proximity Read ↗

BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAFV600E (mutant) papillary thyroid carcinoma progression and sorafenib resistance.Semantic proximity Read ↗

BRAF-Oncogene-Induced Senescence and the Role of Thyroid-Stimulating Hormone Signaling in the Progression of Papillary Thyroid Carcinoma.Semantic proximity Read ↗

USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAFV600E-mutant thyroid cancer via ferroptosis.Semantic proximity Read ↗

Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.Semantic proximity Read ↗

Fatty acid oxidation drives Acetyl-CoA-dependent H3K9ac reprogramming to promote adaptive resistance to BRAFV600E inhibition in thyroid cancerSemantic proximity Read ↗

BRAFV600E/p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer.Semantic proximity Read ↗

Autophagy sustains mitochondrial respiration and determines resistance to BRAF V600E inhibition in thyroid carcinoma cellsSemantic proximity Read ↗

Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF.Semantic proximity Read ↗

Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.Semantic proximity Read ↗

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.